Sellas Life Sciences Group, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
SELLAS Life Sciences Group announces its 2026 Annual Meeting of Stockholders to be held virtually on June 16, 2026, detailing proposals for director elections, auditor ratification, equity plan amendments, executive compensation, and meeting adjournment.
NASDAQ
DEFA14A: SELLAS Life Sciences Updates Proxy Statement Following Auditor Merger, Confirms 'Going Concern' Note
SELLAS Life Sciences Group, Inc. has issued a supplement to its 2025 Annual Meeting proxy statement, announcing the appointment of Baker Tilly US, LLP as its new independent auditor following a merger involving its previous auditor, Moss Adams LLP, while also noting a 'going concern uncertainty' in past financial statements.
NASDAQ
SELLAS Life Sciences Group announces its 2025 Annual Meeting of Stockholders to be held on June 17, 2025, featuring proposals including director elections, auditor ratification, ESPP amendment, and executive compensation.
NASDAQ
DEF: SELLAS Life Sciences Group Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
SELLAS Life Sciences Group will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on director elections, auditor ratification, an employee stock purchase plan amendment, executive compensation, and other matters.
NASDAQ
DEFA14A: SELLAS Life Sciences Group, Inc. Sets Date for 2024 Annual Meeting, Outlines Voting Proposals
SELLAS Life Sciences Group, Inc. announces its 2024 Annual Meeting and provides details on voting proposals, including the election of directors, ratification of the accounting firm, and executive compensation.
NASDAQ
SELLAS Life Sciences Group, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.